AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
This launch is part of the company's strategy to expand its nutraceutical portfolio
Subscribe To Our Newsletter & Stay Updated